Shingles 2026 Update

Shingles (herpes zoster) is a vaccine-preventable disease that causes significant pain and complications. With recent changes to the National Immunisation Program and the deregistration of Zostavax in December 2024, nurse immunisers need to stay current with ATAGI recommendations for Shingrix. This CPD module provides an evidence-based 2026 update on shingles, covering clinical presentation, at-risk populations, current NIP eligibility, and safe vaccine preparation and administration. Designed for immunisers practising in Australia, it supports confident, accurate, and person-centred vaccination practice.

Shingles 2026 Update

Shingles (herpes zoster) is a vaccine-preventable condition that causes significant pain and complications. With recent changes to the National Immunisation Program and the deregistration of Zostavax in December 2024, nurse immunisers need to stay current with ATAGI recommendations for Shingrix.

This CPD module provides an evidence-based 2026 update on shingles, covering clinical presentation, at-risk populations, current NIP eligibility, and safe vaccine preparation and administration. Designed for immunisers practising in Australia, it supports confident, accurate, and person-centred vaccination practice.

Your price: 15.00

Quantity:

Members: $0.00

Non-Members: $15.00

Content Type: Elearning module

CPD Hours: 1.00

Created: Tuesday, 28 July 2026

Area/s of Study

Clinical skills
Community and primary health
Immunisation

Related CPD courses


Pain Assessment & Management Pain is a complex, multidimensional experience that affects physical, psychological, and social wellbeing. This module equips nurses with a thorough understanding of pain’s origins, mechanisms, and classifications, covering both physiologic....
Fundamentals of Neurological Assessment Enhance your clinical expertise with this focused module on neurological assessment. Learn to identify patients at risk of neurological conditions, perform accurate GCS and AVPU assessments, and evaluate cranial nerve function, neurological....
Lymphoedema Management It is estimated that one person in every 6000 will develop Primary Lymphoedema, with the incidence of Secondary Lymphoedema being greater than 20% in cancer survivors. Lymphoedema is associated with many physical and psychological chall....
Tasmanian Eliminate Hepatitis C Australian Outreach Project Join the Tasmanian Region Leadership team and invited guest speaker Megan Hughes in the upcoming webinar Tasmanian Eliminate Hepatitis C Australian Outreach Project (TEHCAO). Key learning objectives - Introduce the concept of the Elimi....